<p><strong>Alert</strong>:     <a class="text-black ps-2" href="https://graniteshares.com/media/qosfbc5p/grsh-compulsory-redemption-notice-lse-20240927.pdf" tabindex="-1">Early Redemption Event of certain classes of ETP Securities</a></p>

AstraZeneca Q2 2024 Earnings

Posted:
AstraZeneca Q2 2024 Earnings

AstraZeneca's Robust Q2 Earnings, Increases Full-Year Guidance

AstraZeneca for the second quarter reported total revenue of $12.938 billion, which increased by 13% on a Year-on-Year (YoY) basis. Moreover, On a half-year basis, total Revenue was up by 18% YoY, which stood at $25.617 billion. The revenue growth was driven by an 18% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines.

On a segment basis, total revenue growth from Oncology, cardiovascular, renal and metabolism (CVRM), and respiratory & immunology (R&I) each increased by 22%, while Rare Disease saw a 15% rise compared to the previous year. Cancer drug sales experienced significant growth, with revenue from collaborations up by 49% on a CER basis. Global demand drove a 12% increase in Tagrisso sales, and Calquence sales rose by 22%.

On 25th July, British pharmaceutical giant AstraZeneca reported a second-quarter profit before tax of $2.40 billion, a 15% increase from $2.09 billion the same quarter the previous year.

Earnings per share rose to $1.24, up 6% from $1.17 last year. However, core earnings per share decreased by 8% to $1.98 from the previous year's figure.

Core product sales gross margin remained steady at 82%, while core earnings per share rose by 5% to $4.03 in the first half of 2024.

The earnings statement highlighted that the increase in core earnings per share was lower than the total revenue growth. This discrepancy was attributed to significant gains recognized in the previous year, including a $241 million gain from the disposal of Pulmicort Flexhaler US rights in the first quarter of 2023 and a $712 million gain from updates to contractual arrangements for Beyfortus in the second quarter of last year.

The Anglo-Swedish pharmaceutical increased its interim dividend by 7 US cents to $1 (77.6 pence, 10.79 SEK) and upgraded its guidance for fiscal year 2024.

Outlook

The company now expects total revenue and core earnings per share to grow by a mid-teens percentage at CER, up from the previously forecasted low double-digit to low teens percentage.

AstraZeneca CEO Pascal Soriot stated, "Building on our strong growth in the first half of the year and continued underlying demand for our medicines, we are upgrading our FY 2024 guidance for both Total Revenue and Core EPS." He also set a new revenue target of $80 billion (€73.8 billion) by 2030, highlighting the substantial growth potential from both approved medicines and those in the late-stage pipeline.

Under Soriot's leadership since 2012, cancer treatment has been a key focus, demonstrating the success of the British firm.

Looking ahead, AstraZeneca may pursue a market share in weight-loss drugs for obesity treatment, driven by the fast-growing demand. At the end of 2023, AstraZeneca and Chinese biotech Eccogene reached an exclusive license agreement for ECC5004, an oral once-daily pill.

This treatment is expected to be more affordable than the current popular injections from Novo Nordisk. The deal underscores AstraZeneca's ambition to compete with global rivals such as Novo Nordisk and Eli Lilly & Co., potentially accelerating the company's growth further.

Visit Us: https://graniteshares.com/institutional/uk/en-uk/

Capital at Risk | Sophisticated Investors Only 

Sources:

  1. AstraZeneca
  2. The Wall Street Journal

Leverage AstraZeneca ETPs by GraniteShares

Leverage ETPs by GraniteShares

Product name Ticker
USD EUR GBX

GraniteShares 3x Long AstraZeneca Daily ETP

-

-

3LAZ

GraniteShares 3x Short AstraZeneca Daily ETP

-

-

3SAZ

GraniteShares 3x Short FATANG Daily ETP

3SFT

3S3E

3S3P

GraniteShares 3x Long FATANG Daily ETP

3FTG

3FTE

3FTP

GraniteShares FATANG ETP

FTNG

FTNE

FTNP

GraniteShares 1x Short FATANG Daily ETP

SFTG

SFTE

SFTP

 

Disclaimer

This is a disclaimer stating that all trading and investing comes with risks. Always do your research and do not invest more than you can afford to spend. GraniteShares accepts no responsibility for any loss or damage resulting directly or indirectly from the use of this blog or the contents. 

This blog does not constitute an offer to buy or sell or a solicitation of an offer to buy securities in any company. Nothing contained herein constitutes investment, legal, tax or other advice nor is to be relied upon in making an investment or other decision. No recommendation is made positive or otherwise, regarding individual securities or investments mentioned herein. Any summary list of risk factors does not purport to be a complete enumeration or explanation of the risks involved in a particular investment. Prospective clients must consult with their own legal, tax and financial advisers before deciding to invest. This email contains the opinions of the author and such opinions are subject to change without notice. The source of data is GraniteShares unless otherwise stated. No guarantee is made to the accuracy of the information provided which has been obtained from sources believed to be reliable. This email and the information contained herein is intended only for the use of persons (or entities they represent) to whom it has been provided. Past performance is not a reliable indicator of future results.  The value of an investment may go down as well as up and can result in losses, up to and including a total loss of the amount initially invested. Investments may involve numerous risks including, among others, company risks, general market risks, credit risks, foreign exchange risks, interest rate risks, geopolitical risks and liquidity risks.  Please note that GraniteShares short and leveraged Exchange Traded Products are for sophisticated investors.

GraniteShares Limited is contracted by GraniteShares Jersey Limited to provide operating and marketing services.

f